Showing results (1-10 of 148) with videos related to

Sort By:
Pageof 15
International Journal of Clinical Oncology|September 2, 2005
Non-small-cell lung cancer: reirradiation for loco-regional relapse previously treated with radiation therapyTakuhito Tada, Haruyuki Fukuda, Kaoru Matsui, et al.
Chest|March 16, 2006
Angled forceps used for transbronchial biopsy in which standard forceps are difficult to manipulate: a comparative studyShinji Sasada, Yoshitaka Ogata, Masashi Kobayashi, et al.
Lung Cancer (Amsterdam, Netherlands)|February 24, 2011
Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancerTakayuki Shiroyama, Kiyoshi Komuta, Fumio Imamura, et al.
Investigational New Drugs|April 13, 2011
A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumorsAkira Fukutomi, Kiyohiko Hatake, Kaoru Matsui, et al.
Journal of Medical Case Reports|July 10, 2024
Stereotactic body radiation therapy for multiple lung cancers in a patient with six primary cancers: a case reportNaoko Ishida, Kenji Nagata, Jyunki Fukuda, et al.
Respiratory Medicine Case Reports|March 18, 2022
A case of renal cell carcinoma with late recurrence in the bilateral hilar lymph nodes twenty years after surgeryYusuke Sakurai, Hiroyuki Matsuura, Yuri Oshima, et al.
Anticancer Research|July 5, 2020
The Association Between Extracellular Water-to-Total Body Water Ratio and Therapeutic Durability for Advanced Lung CancerYoshimi Noda, Hidekazu Suzuki, Tomohiro Kanai, et al.
Oncology Letters|June 25, 2014
Important factors for achieving survival of five years or more in non-small cell lung cancer patients with distant metastasisTomonori Hirashima, Hidekazu Suzuki, Norio Okamoto, et al.
Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|June 22, 2005
[A case of adenocarcinoma of lung with idiopathic pulmonary fibrosis, showing 1 8-fluorodeoxyglucose uptake in positron emission tomograhy]Takayuki Takimoto, Shinji Sasada, Tadahiro Yamadori, et al.
Lung Cancer (Amsterdam, Netherlands)|December 25, 2012
Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutationsKazuhiro Asami, Tomohisa Okuma, Tomonori Hirashima, et al.
Pageof 15